F 200

Drug Profile

F 200

Alternative Names: EOS 200-F; Eos 200F; F-200; Ocular neovascularisation therapies - Protein Design Labs

Latest Information Update: 17 Mar 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Class Eye disorder therapies; Fab fragments
  • Mechanism of Action Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 17 Mar 2005 Discontinued - Preclinical for Age-related macular degeneration in USA (Ophthalmic)
  • 12 Oct 2004 Preclinical data from a media release have been added to the Eye Disorders pharmacodynamics section
  • 23 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top